CMS decision opens ‘massive’ patient pool for Medtronic, says BTIG

BTIG analyst Ryan Zimmerman keeps a Neutral rating on Medtronic (MDT) after Centers for Medicare and Medicaid Services provided a proposed national coverage decision for renal denervation. As anticipated, CMS is proposing to cover renal denervation for uncontrolled hypertension, the analyst tells investors in a research note. BTIG says that while the news was expected, it is still a win for Medtronic. The company has been preparing sites for coverage with the launch of Symplicity Spyral, the firm points out. BTIG believes the decision opens up Medtronic to a “massive” potential patient pool.